New Survey SHINEs Light on Unmet Needs

Apnimed’s SHINE survey puts the spotlight on the pressing needs of the OSA community.

News: Completed Phase 3 Trial Enrollment

Our two Phase 3 clinical trials in OSA have completed enrolling participants and are ready to move forward.

Community Connect: Read OSA Stories

Challenges, learnings, and hope: Four people share their real-life experiences of living with OSA.
A biological process for oxygenation A biological process for oxygenation

AD109:

A Novel Neuromuscular Approach to Improve Oxygenation

Our investigational oral therapy AD109 is designed to simplify treatment and make it more broadly acceptable to those living with OSA who are untreated and undertreated.

More About AD109
Molecule

Apnimed:

Innovation in Oxygenation

We discover, develop, and commercialize novel oral therapies that address the underlying neuromuscular dysfunction of sleep-related breathing diseases to help improve oxygenation.

About Apnimed
Barry Wohl

Our most advanced clinical candidate AD109 is a reflection of our focus on designing solutions that may have potential for sleep apnea patients.

Barry Wohl

Chief Business Officer

Landmark Topline Phase 3
AD109 Data in OSA

Read More